Population
In vitro model of human ether-a-gogo-related gene K channels with Long QT Syndrome Type 2 mutations
Design
Preclinical
Authors
Loading...
May guide non-blocking chaperone design for LQT2; hypothesis-generating in animal models and should not yet change practice.
Pharmacological chaperones (HERG channel blockers) can rescue trafficking-deficient HERG G601S mutations by binding to the inner cavity, providing a structural basis for designing non-blocking chaperones to treat LQT2.
Ficker et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: